BioSpace News Archive

Business

ICON Issues Financial Guidance for Full Year 2019

Announces intention to repurchase up to 1 million shares during 2019.

January 8, 2019
·
4 min read
Business

Sharon Callahan of TBWA/WorldHealth Named 2019 Woman of the Year by the Healthcare Businesswomen’s Association

Sharon Callahan, Chief Executive Officer of TBWA/WorldHealth and Chief Client Officer at Omnicom Health Group, has been named Woman of the Year by the Healthcare Businesswomen’s Association (HBA).

January 8, 2019
·
4 min read
Policy

Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Epclusa® (Sofosbuvir/Velpatasvir)

Epclusa is the First Approved Treatment for Adults with Chronic Hepatitis C Virus with Decompensated Cirrhosis in Japan -

January 8, 2019
·
7 min read
Business

Calliditas Therapeutics Appoints Andrew Udell to VP Commercial, North America

Calliditas Therapeutics AB today announced the appointment of Andrew Udell as Vice President, North America Commercial, effective February 1, 2019.

January 8, 2019
·
4 min read
Business

AgroSavfe Announces Adrian Percy as New Independent Board Member

AgroSavfe NV announced today that it has appointed Dr Adrian Percy as new Board Member to its Board of Directors.

January 8, 2019
·
2 min read
Business

4D pharma plc: Appointment of Independent Non-Executive Directors

4D pharma plc today announces the appointment of Ed Baracchini, PhD, and Professor Axel Glasmacher, MD, as independent Non-Executive Directors with immediate effect.

January 8, 2019
·
3 min read
FSD Pharma Completes Harvest and Passes Analytical Testing of Second Lot

Company in position for pre-sales license inspection, last step to issuance of a Sales License

January 8, 2019
·
3 min read
Business

FlowMetric Europe Headquarters Moves to Zambon OpenZone Campus

FlowMetric Europe is excited to announce that it will be opening its expanded European Headquarters office within the OpenZone campus (www.openzone.it), effective January 28th, 2019

January 8, 2019
·
3 min read
Novartis investigational therapy crizanlizumab (SEG101) receives FDA Breakthrough Therapy designation for the prevention of vaso-occlusive crises in sickle cell disease

Crizanlizumab is a monthly infusion under development to prevent pain crises (also called vaso-occlusive crises, or VOCs) in patients with sickle cell disease

January 8, 2019
·
8 min read
Biotech Bay

PQ Bypass Announces $60 Million Financing to Advance New Therapeutic Approach to Peripheral Arterial Disease

Funds Will Support Pivotal Trial of Novel DETOUR System Designed for Patients with Tough to Treat Long Blockages in Leg Arteries

January 8, 2019
·
5 min read